OOS · Phase I / Phase II · FDA 2006 guidance
OOS investigations with a clear Phase I and Phase II record.
Guide investigators through laboratory and manufacturing phases, keep the evidence together and record each signed decision.
Enforced Phase I / Phase II sequence
V5 blocks Phase II from opening until Phase I lab-error assessment is closed with signed rationale.
Pre-Approved Hypothesis Testing
Any retest requires a written hypothesis, an approver signature, and a documented sampling plan — before the second injection runs.
Automatic Trending Across Batches, Assays, Analysts and Instruments
OOS records link to the assay, the column, the analyst and the equipment — trends surface at review, not at inspection.
What goes wrong today3 common problems
Retesting into Compliance
Analysts retest until they get a passing result — with no documented hypothesis, no pre-approved justification, and no idea the FDA calls that a 483 waiting to happen.
Phase I skipped
Everyone jumps to manufacturing investigation before ruling out lab error, so the real root cause is buried under process theories.
Trends Invisible
Individual OOS records close in isolation. Nobody sees the same assay drifting across three batches until the FDA does.
Everything V5 does here5 capabilities
Enforced Phase I / Phase II sequence
V5 blocks Phase II from opening until Phase I lab-error assessment is closed with signed rationale.
Pre-Approved Hypothesis Testing
Any retest requires a written hypothesis, an approver signature, and a documented sampling plan — before the second injection runs.
Automatic Trending Across Batches, Assays, Analysts and Instruments
OOS records link to the assay, the column, the analyst and the equipment — trends surface at review, not at inspection.
MHRA / FDA / EMA Decision Tree Built In
Confirmed OOS routes to batch rejection or investigation extension automatically; invalid OOS requires documented invalidation criteria.
Full Linkage to Deviation, CAPA and Batch Record
One OOS opens the deviation, holds the batch, links to the CAPA and appears in the APQR — no separate systems.
How it works, step by step5 steps
OOS lifecycle in V5.
- Result Flagged OOS. LIMS/instrument capture triggers investigation.
- Lab Investigation. Method, equipment, analyst, standards reviewed and signed.
- Manufacturing Investigation. Only if Phase I complete; process, materials, environment reviewed.
- Forward Assessment. Other batches on same context surfaced.
- Disposition & CAPA. Batch disposition e-signed; CAPA raised if warranted.
What to look for when choosing
OOS management is one of the most-cited lab investigation topics. Criteria below distinguish real Phase I/II workflow from a checkbox tracker.
Phase I / Phase II gating
Are Phase I (lab error investigation) and Phase II (manufacturing) enforced as sequential gates with defined evidence? Phase I completes with signed rationale before Phase II opens; skipping is blocked.
Result Invalidation Authority
Is invalidation restricted, e-signed and requires objective evidence? Invalidation requires objective evidence and quality-unit e-sig; audit trail immutable.
Retest and Resample Rules
Are retest/resample rules formalised in the workflow? Retest/resample rules configured per method; violations blocked.
Batch Impact Assessment
Does OOS drive an impact assessment across other batches on the same equipment/reagent/method? Live impact assessment across analytical genealogy.
MHRA / FDA Guidance Alignment
Are the workflow steps aligned to FDA Guidance for Industry: Investigating OOS Test Results? Workflow mirrors FDA guidance steps.
V5 Compared with Other Approaches
OOS handling: paper vs QMS module vs V5.
| capability | spreadsheet | legacy Qms | v5 |
|---|---|---|---|
| Phase I / II gating | Manual | Sometimes | Enforced sequential |
| Invalidation control | Signature | Optional | Enforced with objective evidence |
| Batch impact | Manual | Report | Live from genealogy |
| Guidance alignment | Author-dependent | Static | Native workflow |
Regulations this supportsYour quality team stays responsible for compliance
OOS clauses inspectors cite.
21 CFR 211.192
OOS opens investigation; closure requires rationale.
FDA Guidance for Industry (OOS)
Phase I gate with defined evidence.
EU GMP Chapter 6 §6.35
Full investigation record with document trail.
MHRA GMP Data Integrity Guidance
Retest requires objective justification captured in-system.
Standards Referenced
- FDA Guidance for Industry: Investigating OOS Test Results (2006)
- 21 CFR 211.192 (production record review)
- US v. Barr Laboratories (foundational OOS case law)
- MHRA OOS Guidance 2017
- EU GMP Annex 11 (computerised systems)
Common questions3 answers
- How does V5 stop 'testing into compliance'?
- Any retest requires a written hypothesis and an approver e-signature before the second injection runs — the retest cannot be recorded without them. The audit trail proves the hypothesis existed before the result did.
- Does V5 enforce Phase I before Phase II?
- Yes. Phase II (manufacturing investigation) cannot be opened until Phase I (laboratory assessment) is closed with signed rationale for confirmed or invalidated OOS.
- Can V5 trend OOS across products and analysts?
- Yes — every OOS is tagged with assay, method, column/instrument, analyst and batch. Trending dashboards surface drift before it becomes an inspection finding.